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SETTING: Public sector facilities in Malawi providing anti-
retroviral therapy (ART) to human immunodeﬁciency
virus (HIV) positive patients, including those with tuber-
culosis (TB).
OBJECTIVES: To compare 6-month and 12-month cohort
treatment outcomes of HIV-positive TB patients and HIV-
positive non-TB patients treated with ART.
DESIGN: Retrospective data collection using ART patient
master cards and ART patient registers.
RESULTS: Between July and September 2005, 7905 pa-
tients started ART, 6967 with a non-TB diagnosis and
938 with a diagnosis of active TB. 6-month cohort out-
comes of non-TB and TB patients censored on 31 March
2006 showed signiﬁcantly more TB patients alive and
on ART (77%) compared with non-TB patients (71%)
(P   0.001). Between January and March 2005, 4580
patients started ART, 4179 with a non-TB diagnosis and
401 with a diagnosis of active TB. 12-month cohort out-
comes of non-TB and TB patients censored on 31 March
2006 showed signiﬁcantly more TB patients alive and on
ART (74%) compared with non-TB patients (66%) (P  
0.001). Other outcomes of default and transfer out were
also signiﬁcantly less frequent in TB compared with non-
TB patients.
CONCLUSION: HIV-positive TB patients on ART in
Malawi have generally good treatment outcomes, and
more patients need to access this HIV treatment.
KEY WORDS: tuberculosis; antiretroviral therapy; treat-
ment outcomes; Malawi
WITH THE START of the World Health Organiza-
tion’s (WHO’s) ‘3 by 5’ initiative, many resource-poor
countries have started scaling up antiretroviral ther-
apy (ART) for their human immunodeﬁciency virus
(HIV) infected communities. Although the target was
not reached in 2005, excellent progress was made. In
Africa, for example, 840000 patients were started on
ART by December 2005.1
HIV-positive patients with tuberculosis (TB) are all
potentially eligible for ART, because they are in either
WHO Clinical Stage 3 (pulmonary tuberculosis [PTB])
or Stage 4 (extra-pulmonary tuberculosis [EPTB]).2 In
principle, HIV-positive TB patients should beneﬁt from
ART, which leads to a reduction in HIV-related mor-
tality and HIV-related recurrence of TB disease. Reports
on small numbers of patients treated in the UK,3 Tai-
wan4 and Thailand5 indicate a good outcome in HIV-
positive TB patients treated with ART, with the report
from Taiwan showing similar responses between HIV-
infected TB and non-TB patients.4 To our knowledge
there have been no reports on outcomes of HIV-infected
TB patients treated with ART in the routine health sys-
tem in sub-Saharan Africa.
Every 3 months, the HIV Unit of the Malawian Min-
istry of Health and its partners conduct supervisory and
monitoring visits to all sites in the country that are deliv-
ering ART in the public sector. Data are collected on
numbers and characteristics of patients starting ART
and their outcomes. We used these structured visits to
obtain additional information on outcomes of patients
with TB who had been started on ART, and we com-
pared their outcomes with those for non-TB patients.
METHODS
Background of ART and anti-tuberculosis treatment
ART scale-up in Malawi
The process of ART scale-up has already been described
in previous articles,6,7 and only the main elements will
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be described below. A standardised, structured ap-
proach is used. This includes a focus on the use of one
generic, ﬁxed-dose combination treatment with stav-
udine, lamivudine and nevirapine (NVP) to be deliv-
ered free of charge to HIV-positive eligible patients; a
standardised system of registration, monitoring and
reporting of cases and outcomes; and quarterly super-
vision and evaluation of all ART sites. Two alternative
ﬁrst-line regimens (for serious side effects of ART drugs)
and one second-line regimen (for ART drug failure)
have been placed in central hospitals and two district
hospitals, and a referral system set up so that patients
in need can access appropriate therapy. Between 2004
and the present, health facilities have gradually become
accredited and started ART delivery services, and by
March 2006, 66 sites were accredited and delivering
ART using the national standardised systems.
Referral for ART and start of therapy
When a patient is found to be HIV-positive, he/she is
referred to the ART clinic for clinical staging. If the
patient is found to be eligible for ART (assessed as
WHO Clinical Stage 3 or 4, or with a CD4 lympho-
cyte count  200/mm3), he/she is asked to attend, with
a guardian, a group counselling session conducted by
one of the ART clinic staff for education about ART.
Following this session the patient is asked to return a
few days later for individual counselling and start of
ART. Patients are then followed up, ﬁrst at 2 weeks
and thereafter at 4-week intervals, with assessments
and drugs distributed from the ART clinic.
Anti-tuberculosis treatment and referral of 
TB patients for ART
TB patients are diagnosed, registered and treated ac-
cording to national guidelines, using a standardised
approach8 and following WHO guidelines.9 New pa-
tients are treated with a 2-month initial phase of
rifampicin (RMP), isoniazid (INH), and pyrazinamide
(PZA) (with additional ethambutol [EMB] for sputum
smear-positive patients), followed by a 6-month contin-
uation phase of INH and EMB. Patients with recurrent
TB are given a standard retreatment regimen.8,9 As a pa-
tient group earmarked for diagnostic HIV testing and
counselling, TB patients should be offered this service,
usually during the ﬁrst 2 weeks of the initial phase of
anti-tuberculosis treatment. For patients who are HIV-
positive, ART is deferred until the continuation phase of
anti-tuberculosis treatment due to concerns about drug-
drug interactions with RMP and NVP.10 HIV-positive
TB patients who are started on ART are followed up
monthly on the same day, and have to attend the TB
clinic for monitoring and anti-tuberculosis medica-
tion and the ART clinic for monitoring and ART drugs.
Monitoring and evaluation for ART
During the monthly ART monitoring visits, vital data
are recorded using standardised monitoring tools,
particularly the ART patient master cards and ART
register, which have been described previously.7 Stan-
dardised treatment outcomes (Table 1) are recorded
every month in the master cards and updated in the
ART Register. Every 3 months a quarterly cohort
analysis is performed on the most recent 3-month co-
hort of patients started on ART and the cumulative
cohort of patients ever started on therapy. Facilities
record case-ﬁnding characteristics and treatment out-
comes at a set point in time, and these are checked
and collated by the HIV Unit and its partners during
the quarterly supervisory visits. These have also been
described previously.11
Data collection
By the end of March 2006, there were 66 sites in the
public sector delivering ART to patients. They were all
visited between April and June 2006. Data for quar-
terly and cumulative cohort analyses were collected into
structured proforma and then entered into an Excel
spreadsheet (Microsoft Corp, Redmond, WA, USA) for
collation. Sixty sites had started patients on ART be-
tween 1 July and 30 September 2005, and their treat-
ment outcomes were censored on 31 March 2006 to
provide a 6-month cohort outcome analysis; it is recog-
nised that in effect this means an analysis of patient out-
comes 6–9 months after starting ART. Thirty-ﬁve sites
had started patients on ART between 1 January and
31 March 2005, and their treatment outcomes were
also censored on 31 March 2006 to provide a 12-month
cohort outcome analysis; it is also recognised that, in ef-
fect, this means an analysis of patient outcomes 12–15
months after starting ART. In addition, during these
same two quarterly periods, HIV-positive patients with
actively treated PTB or EPTB as reasons for starting
ART were identiﬁed from the ART patient master cards,
and their outcomes were censored on 31 March 2006
to provide a 6-month and 12-month outcome analysis
for TB patients.
Analysis
Six- and 12-month treatment outcomes were docu-
mented for patients who were started on ART because
Table 1 Standardised treatment outcomes for patients
on ART
Outcome Deﬁnition
Alive and on ART Patient who is alive and on ART at the facility 
where he/she is registered
Dead Patient who dies for any reason while on ART
Defaulted Patient who has not attended the ART clinic for 
3 months or longer for no known reason
Stopped Patient who stops treatment for any reason 
during the course of treatment
Transferred out Patient who has been permanently transferred 
out to another treatment facility
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of diagnosis with active TB, and data were also disag-
gregated for those with PTB and EPTB. The numbers
of TB patients and their outcome data were subtracted
from all patients started on ART during the same time
periods, and a calculation was made for survival out-
comes for non-tuberculosis patients. Differences in
treatment outcomes between groups were compared
using the  2 test. Relative risks (RR) and 95% conﬁ-
dence intervals (CIs) were obtained, with differences
at the level of 0.05 being regarded as signiﬁcant.
RESULTS
Between 1 July and 30 September 2005, 7905 patients
started ART—6967 with a non-TB diagnosis and 938
(12% of all patients on ART) with a diagnosis of ac-
tive TB (673 PTB and 265 EPTB). The 6-month cohort
outcomes of non-TB and TB patients censored on 31
March 2006 are shown in Table 2. At 6 months, signif-
icantly more TB patients were alive and signiﬁcantly
fewer TB patients had defaulted or transferred out
compared with non-TB patients. Treatment outcomes
were not signiﬁcantly different between patients with
active PTB and EPTB.
Between 1 January and 31 March 2005, 4580 pa-
tients started ART—4179 with a non-TB diagnosis
and 401 (9% of all patients on ART) with a diagnosis of
active TB (288 PTB and 113 EPTB). The 12-month
cohort outcomes of non-TB and TB patients censored
on 31 March 2006 are shown in Table 3. At 12 months,
signiﬁcantly more TB patients were alive and signiﬁ-
cantly fewer TB patients had defaulted or transferred
out compared with non-TB patients. Treatment out-
comes were similar between patients with active PTB
and EPTB, except that signiﬁcantly fewer patients
with active PTB had transferred out compared with
EPTB (RR 0.34, 95%CI 0.16–0.70, P   0.01).
DISCUSSION
This is one of the ﬁrst reports from sub-Saharan Africa
that looks at treatment outcomes in the routine setting
of HIV-positive patients who have been diagnosed and
treated for TB and then started on ART. The treatment
outcomes are in general better than for patients without
TB. Approximately 75% of HIV-positive TB patients
are alive and on ART 6–12 months after starting ART.
It is likely, although not yet proven, that patients who
transfer out are also alive and taking ART at their new
treatment facility. If this is the case, then the proportion
of HIV-positive TB patients who are alive at 6 and 12
months after starting ART would increase to approxi-
mately 80%. One possible reason for better outcomes
in TB patients compared with non-TB patients may be
because TB patients have 2 months to stabilise on their
anti-tuberculosis treatment before starting ART, giving
Table 2 Six-month outcomes in a quarterly cohort of TB patients and non-TB patients started on ART
in Malawi between July and September 2005, with outcomes censored on 31 March 2006
Active PTB
patients
n (%)
Active EPTB
patients
n (%)
All types
of TB
patients
n (%)
Non-TB
patients
n (%) RR (95%CI)* P value
Started on ART 673 265 938 6967
Alive 521 (77) 203 (77) 724 (77) 4979 (71) 1.08 (1.04–1.12)  0.001
Dead 69 (10) 36 (14) 105 (11) 867 (12) 0.90 (0.74–1.09) NS
Defaulted 48 (7) 11 (4) 59 (6) 595 (9) 0.74 (0.57–0.95)  0.05
Stopped 5 (1) 1 (0) 6 (1) 53 (1) 0.84 (0.36–1.95) NS
Transferred out 30 (5) 14 (5) 44 (5) 473 (7) 0.69 (0.51–0.93)  0.05
*Treatment outcome relative risks are compared between patients with all types of TB and non-TB patients.
TB   tuberculosis; ART   antiretroviral treatment; PTB   pulmonary tuberculosis; EPTB   extra-pulmonary tuberculosis; RR   relative
risk; CI   conﬁdence interval; NS   not signiﬁcant.
Table 3 Twelve-month outcomes in a quarterly cohort of TB patients and non-TB patients started on ART 
in Malawi between January and March 2005, with outcomes censored on 31 March 2006
Active PTB
patients
n (%)
Active EPTB
patients
n (%)
All types
of TB
patients
n (%)
Non-TB
patients
n (%) RR (95%CI)* P value
Started on ART 288 113 401 4179
Alive 218 (76) 77 (68) 295 (74) 2678 (66) 1.15 (1.08–1.22)  0.001
Dead 33 (12) 11 (10) 44 (11) 536 (12) 0.86 (0.64–1.14) NS
Defaulted 21 (7) 10 (9) 31 (8) 479 (11) 0.67 (0.48–0.96)  0.05
Stopped 4 (1) 1 (1) 5 (1) 47 (1) 1.11 (0.44–2.77) NS
Transferred out 12 (4) 14 (12) 26 (5) 439 (10) 0.62 (0.42–0.90)  0.05
*Treatment outcome relative risks are compared between patients with all types of TB and non-TB patients.
TB   tuberculosis; ART   antiretroviral treatment; PTB   pulmonary tuberculosis; EPTB   extra-pulmonary tuberculosis; RR   relative
risk; CI   conﬁdence interval; NS   not signiﬁcant.Outcomes of TB patients on ART in Malawi 415
them time to stabilise from their opportunistic infection,
in contrast to non-TB patients, who are often given a
much shorter period in which to stabilise.
It appears from the national quarterly reports on
antiretroviral (ARV) scale-up (source: Ministry of
Health, Malawi) and from studies conducted in sub-
Saharan Africa that there is high early mortality in
patients starting ART, which then decreases with time
on treatment.12 This also appears to be the case in TB
patients starting ART, as the 6-month and 12-month
outcomes of death and default (which might mean
undocumented death)13 are very similar.
This was an operational study conducted within
the routine system, and it therefore has all the limita-
tions of this type of research. Data were not extracted
on variables such as demographic characteristics of
patients, the timing of anti-tuberculosis treatment in
patients started on ART, HIV- or drug-related morbid-
ity or causes of death. During the period of observation,
very few facilities in Malawi were providing reliable
CD4-lymphocyte count measurements, and we there-
fore have no data on patients’ degree of immunodeﬁ-
ciency. However, it was country-wide, the routine sys-
tems for monitoring patients using master cards and
registers are robust and regularly checked by supervis-
ing teams, and we believe that the results are reliable
and representative. The use of 6-month and 12-month
quarterly cohort analysis is now well-established and
enables treatment outcome analyses to be carried out
in the routine system. For busy ART facilities and su-
pervising teams with scarce human resources, censor-
ing individual treatment outcomes at a set point in time
is too time-consuming, but cohort treatment outcome
analysis is quick and reliable, provided the registers
are regularly updated.
Several unanswered questions remain. First, al-
though HIV-positive TB patients on ART have a gen-
erally good outcome up to 12 months, we do not know
how initiation of ART affects TB-speciﬁc treatment
outcomes. These outcomes are determined by the pro-
portion of TB patients in a cohort who actually start
on ART, and the degree of early TB-HIV mortality that
occurs before patients are started on ART. In Malawi,
we are aware that for various reasons only a small pro-
portion of TB patients access ART,14 and that there is
high early mortality in TB patients during the initial
phase of anti-tuberculosis treatment before ART is com-
menced.15 Second, according to the recent WHO guide-
lines, HIV-positive TB patients should be commenced
on ART after 2 months of the initiation phase of anti-
tuberculosis treatment if a CD4 lymphocyte count is
not available to guide decision making.2 We are follow-
ing this guidance in Malawi, but if CD4 testing capacity
increases in the country it may be possible to start pa-
tients earlier. The WHO recommends that TB patients
can start ART 2–4 weeks after starting TB treatment if
they have low CD4 counts  200 cells/mm3, and this
may improve outcomes.2 Third, we do not know
whether there is a marked difference in TB-speciﬁc
treatment outcomes in HIV-positive TB patients started
on ART in the continuation phase compared with
those not on ART, although we suspect there would be
a difference, as a 7-year follow-up study of HIV-posi-
tive TB patients in Malawi showed that the long-term
outcomes are poor if no HIV intervention is given.16
Despite these conundrums, the results of this study
provide reassuring evidence that TB patients started on
ART during the continuation phase of anti-tuberculosis
treatment do well. The climate in which we now work
in sub-Saharan Africa has changed, given the arrival of
ARV drugs and scale-up programmes in most countries
in the region.17 Our results should further encourage
HIV and TB programmes to work together to get more
HIV-positive TB patients on this life-saving medication.
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RÉSUMÉ
CONTEXTE:Les services du secteur public du Malawi as-
surant un traitement antirétroviral (ART) chez les pa-
tients séropositifs pour le virus de l’immunodéficience hu-
maine (VIH), y compris ceux atteints de tuberculose (TB).
OBJECTIFS: Comparer les résultats du traitement dans
les cohortes de 6 mois et de 12 mois chez les patients
séropositifs pour le VIH et tous traités par l’ART, qu’ils
soient TB ou non-TB.
SCHÉMA :Collecte rétrospective des données au moyen
des cartes maîtresses des malades et des registres des pa-
tients sur ART.
RÉSULTATS:Entre juillet et septembre 2005, 7905 pa-
tients ont commencé l’ART dont 6967 avec un diagnostic
non-TB et 938 avec un diagnostic de TB active. Les ré-
sultats de la cohorte de 6 mois chez les patients non-TB
et chez les patients TB, clôturés le 31 mars 2006, ont
montré que le nombre de patients TB en vie était plus
élevé sous traitement ART (77%) par comparaison avec
les patients non-TB (71%) (P   0,001). Entre janvier et
mars 2005, 4580 patients ont commencé l’ART (4179
avec un diagnostic non-TB et 401 avec un diagnostic de
TB active. Les résultats de la cohorte de 12 mois chez les
patients TB et non-TB, clôturés le 31 mars 2006, ont
montré qu’un nombre significativement plus élevé de pa-
tients TB étaient en vie et sous traitement ART (74%)
par comparaison avec les patients non-TB (66%) (P  
0,001). D’autres résultats concernant les abandons et les
transferts vers l’extérieur ont été eux aussi significative-
ment moins fréquents chez les patients TB par com-
paraison avec les non-TB.
CONCLUSION:Au Malawi, les patients TB positifs pour
le VIH et sous ART ont généralement de bons résultats
du traitement et il y a lieu de veiller à ce qu’un plus grand
nombre de patients aient accès à ce traitement du VIH.
RESUMEN
MARCO DE REFERENCIA:Establecimientos del sector
público en Malawi que suministran tratamiento antirre-
trovírico (ART) a pacientes con serología positiva para el
virus de la inmunodeficiencia humana (VIH), incluidos
los pacientes con tuberculosis (TB).
OBJETIVOS:Comparar el desenlace terapéutico en co-
hortes de ART de 6 y de 12 meses, en pacientes con TB
y VIH positivos y pacientes VIH positivos sin TB.
MÉTODOS:Análisis retrospectivo de datos a partir de las
tarjetas de control de tratamiento y de los registros de
pacientes en ART.
RESULTADOS:Entre julio y septiembre de 2005, 7905
pacientes comenzaron ART (6967 sin diagnóstico de TB
y 938 con TB activa). El desenlace en esta cohorte de pa-
cientes en ART de 6 meses, registrado el 31 de marzo de
2006, demostró que había más pacientes vivos con TB
que pacientes vivos sin TB en quienes recibían el ART
(77% contra 71% ; P   0,001). Entre junio y marzo de
2005, 4580 pacientes comenzaron ART (4179 sin diag-
nóstico de TB y 401 con diagnóstico de TB activa). El
desenlace en esta cohorte de pacientes en ART de 12 me-
ses, registrado el 31 de marzo de 2006, demostró que
había más pacientes vivos con TB que pacientes vivos
sin TB en tratamiento (74% contra 66% ; P   0,001).
Ambas diferencias fueron estadísticamente significativas.
Otros desenlaces como abandono y transferencia también
fueron significativamente menos frecuentes en pacientes
con TB que en pacientes sin TB.
CONCLUSIÓN:En general, el desenlace terapéutico de los
pacientes que presentan coinfección por VIH y TB y re-
ciben ART es favorable en Malawi. Es importante ampliar
el acceso de los pacientes al tratamiento contra el VIH.